Get the Stockscreener App
10.29
0.39%
0.04
Amneal Pharmaceuticals Inc stock is traded at $10.29, with a volume of 1.59M.
It is up +0.39% in the last 24 hours and up +5.54% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$10.25
Open:
$10.23
24h Volume:
1.59M
Relative Volume:
0.99
Market Cap:
$3.23B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-15.12
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
+0.00%
1M Performance:
+5.54%
6M Performance:
+35.04%
1Y Performance:
+20.49%
1-Day Range:
$10.13
$10.45
1-Week Range:
$10.13
$10.62
52-Week Range:
$6.685
$10.68
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
10.29 | 3.22B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
145.41 | 65.38B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.10 | 44.75B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.12 | 40.97B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.78 | 22.50B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
415.34 | 19.04B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Brekiya Migraine Autoinjector Launch Could Be a Game Changer for Amneal Pharmaceuticals (AMRX) - Yahoo Finance
Will Amneal Pharmaceuticals Inc. stock reach Wall Street targets2025 Big Picture & Free Daily Entry Point Trade Alerts - newser.com
Does Amneal Pharmaceuticals Inc. show high probability of rebound2025 Buyback Activity & Fast Gain Swing Alerts - newser.com
Is Amneal Pharmaceuticals Inc. stock resilient to inflationMarket Volume Summary & Technical Pattern Alert System - newser.com
Can Amneal Pharmaceuticals Inc. stock beat market expectations this quarterEarnings Risk Summary & High Accuracy Trade Alerts - Fundação Cultural do Pará
Is Amneal Pharmaceuticals Inc. stock a top momentum playTrade Entry Report & Short-Term Trading Opportunity Alerts - newser.com
How high can Amneal Pharmaceuticals Inc. stock go2025 Earnings Impact & AI Enhanced Trading Signals - newser.com
Will Amneal Pharmaceuticals Inc. stock benefit from automationWeekly Trade Report & Safe Capital Growth Trade Ideas - newser.com
How Amneal Pharmaceuticals Inc. stock compares to industry benchmarksWeekly Trend Report & Free Long-Term Investment Growth Plans - Fundação Cultural do Pará
How to manage a losing position in Amneal Pharmaceuticals Inc.Earnings Overview Report & Fast Gaining Stock Strategy Reports - newser.com
Mycophenolate Pregnancy Registry: Key Insights for Investors - TipRanks
What analyst consensus says on Amneal Pharmaceuticals Inc. stockWeekly Trend Summary & Low Risk High Win Rate Stock Picks - newser.com
Why Amneal Pharmaceuticals Inc. stock could outperform in 2025Market Growth Report & Free Weekly Chart Analysis and Trade Guides - Fundação Cultural do Pará
Amneal Launches Brekiya®the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches - The Manila Times
Candlestick signals on Amneal Pharmaceuticals Inc. stock todayJuly 2025 Snapshot & Free Real-Time Market Sentiment Alerts - newser.com
Amneal (NASDAQ: AMRX) launches Brekiya for migraine, exclusive at Walgreens and Sterling - Stock Titan
Published on: 2025-10-27 03:37:22 - newser.com
Published on: 2025-10-26 15:52:31 - newser.com
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.30%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):